Fan Mu
 
                    Education
Ph.D., epidemiology, Harvard University; M.S., epidemiology, Harvard University; M.B.B.S., medicine, Peking University
Summary of Experience
Dr. Mu specializes in the application of advanced epidemiologic methodologies and biostatistical techniques to address a wide array of analytical questions in health care involving evaluation, decision making, and strategy. She has broad experience designing and implementing advanced and innovative data analytics and solutions for life sciences companies. Dr. Mu’s expertise includes real-world evidence development, database analyses, chart review studies, survey research, predictive analytics, systematic and targeted literature reviews, indirect comparisons, and health economic modeling. She has broad experience developing strategies and conducting research to assess the clinical, economic, and humanistic impacts of diseases and treatments in a range of therapeutic areas, including nephrology, immunology, psychiatry, oncology, dermatology, gynecology, and virology. She has consulted to numerous life sciences companies on both novel pipeline agents and products on the market. Dr. Mu’s work has supported health care payers and clinical decision makers in both US and global markets. Her research has been published in peer-reviewed journals and presented at clinical and economic research conferences.
- 
                                                        Hyperkalemia and Risk of Chronic Kidney Disease Progression: A Propensity Score Matched AnalysisKidney360, 2024 
 2024Agiro A, Cook E, Mu F, Greatsinger A, Chen J, Zhao A, Louden E, Colman E, Desa P, Chertow GM 
- 
                                                        Economic burden of recurrent hyperkalemia in patients with chronic kidney diseaseJournal of Managed Care & Specialty Pharmacy, 2024 
 2024Bakris G, Agiro A, Greatsinger A, Mu F, Cook EE, Sundar M, Louden E, Colman E, Desai P 
- 
                                                        Real-World Effectiveness of Benralizumab Among Patients with Asthma and Concomitant Chronic Obstructive Pulmonary DiseaseInternational Journal of Chronic Obstructive Pulmonary Disease, 2024 
 2024Carstens DD, Maselli DJ, Cook EE, Mu F, Chen J, Yang D, DeMartino JK , Chung Y 
- 
                                                        Real-World Effectiveness of Omadacycline and Impact of Unapproved Omadacycline Prescription Claims among Adult Outpatients with Community-Acquired Bacterial Pneumonia or Acute Bacterial Skin and Skin Structure InfectionsJournal of Managed Care & Specialty Pharmacy, 2023 
 2023Lodise TP, Gunter K, Mu F, Gao E, Yang D, Yim E, Sandor S, Berman G 
- 
                                                        Real-World Modifications of Renin-Angiotensin-Aldosterone System Inhibitors in Patients with Hyperkalemia Initiating Sodium Zirconium Cyclosilicate Therapy: The Optimize I StudyAdvances in Therapy, 2023 
 2023Agiro A, Amin AN, Cook EE, Mu F, Chen J, Desai P, Oluwatosin Y, Pollack CV 
- 
                                                        Impact on Hospitalizations of Long-Term Versus Short-Term Therapy with Sodium Zirconium Cyclosilicate During Routine Outpatient Care of Patients with Hyperkalemia: The Recognize I StudyExpert Review of Pharmacoeconomics and Outcomes Research, 2023 
 2023Pollack CV, Agiro A, Mu F, Cook EE, Wirtz EL, Young JA, Betts KA, Brahmbhatt YG 
- 
                                                        Impact of benralizumab on asthma exacerbation-related medical healthcare resource utilization and medical costs: results from the ZEPHYR 2 studyJournal of Medical Economics, 2023 
 2023Chung Y, Maselli DJ, Mu F, Cook EE, Yang D, Young JA, Betts KA, Genofre E, Carstens D 
- 
                                                        Real-world effectiveness of benralizumab: results from the ZEPHYR 1 StudyAnnals of Allergy, Asthma & Immunology, 2022 
 2022Chung Y, Katial R, Mu F, Cook E, Young J, Yang D, Betts K, Carstens D 
- 
                                                        Five-Year Estimated Glomerular Filtration Rate in Adults with Chronic Hypoparathyroidism Treated with rhPTH(1-84): A Retrospective Cohort StudyAdvances in Therapy, 2022 
 2022Ayodele O, Rejnmark L, Mu F, Lax A, Berman R, Swallow E, Gosmanova EO 
- 
                                                        The Economic Burden of Eosinophilic Gastritis and Eosinophilic Enteritis in the United StatesAdvances in Therapy, 2022 
 2022Woolley M, Cook EE, Mu F, Betts KA, Billmyer E, Yim E, Chen J, Wu EQ 
- 
                                                        
- 
                                                        Lower Risk of Cardiovascular Events in Adult Patients with Chronic Hypoparathyroidism Treated with rhPTH(1-84): A Retrospective Cohort StudyAdvances in Therapy, 2022 
 2022Ayodele O, Mu F, Berman R, Swallow E, Rejnmark L, Gosmanova EO, Kaul S 
- 
                                                        Real-world effectiveness after initiating fremanezumab treatment in US patients with episodic and chronic migraine or difficult-to-treat migraineThe Journal of Headache and Pain, 2022 
 2022Driessen MT, Cohen JM, Thompson SF, Patterson-Lomba O, Seminerio MJ, Carr K, Totev TI, Sun R, Yim E, Mu F, Ayyagari R 
- 
                                                        Risk of Thromboembolic Events and Associated Healthcare Costs in Patients with Inflammatory Bowel DiseaseAdvances in Therapy, 2022 
 2022Setyawan J, Mu F, Zichlin ML, Billmyer E, Downes N, Yang H, Azimi N, Strand V, Yarur A 
- 
                                                        The Economic Burden of Thromboembolic Events Among Patients with Immune-Mediated DiseasesAdvances in Therapy, 2022 
 2022Setyawan J, Billmyer E, Mu F, Yarur A, Zichlin ML, Yang H, Downes N, Azimi N, Strand V 
- 
                                                        Real-world effectiveness of fremanezumab in migraine patients initiating treatment in the United States: results from a retrospective chart studyThe Journal of Headache and Pain, 2022 
 2022Driessen MT, Cohen JM, Patterson-Lomba O, Thompson SF, Seminerio M, Carr K, Totev TI, Sun R, Yim E, Mu F, Ayyagari R 
- 
                                                        Real-World Management of Hyperkalemia in the Emergency Department: An Electronic Medical Record AnalysisAdvances in Therapy, 2022 
 2022Davis J, Israni R, Betts KA, Mu F, Cook EE, Anzalone D, Szerlip H, Yin L, Uwaifo GI, Wu EQ 
- 
                                                        Association of Calcium and Phosphate Levels with Incident Chronic Kidney Disease in Patients with Hypoparathyroidism: A Retrospective Case-Control StudyInternational Journal of Endocrinology, 2022 
 2022Gosmanova EO, Ayodele O, Chen K, Cook EE, Mu F, Young JA, Rejnmark L 
- 
                                                        Inpatient Management and Post-Discharge Outcomes of HyperkalemiaHospital Practice, 2021 
 2021Davis J, Israni R, Mu F, Cook E, Szerlip H, Uwaifo G, Fonseca V, Betts K 
- 
                                                        Risk of Chronic Kidney Disease in Adult Patients With Chronic Hypoparathyroidism Treated With rhPTH(1-84) Compared With a Historical Control CohortEuropean Congress of Endocrinology, 2021 
 2021Gosmanova EO, Ayodele O, Sherry N, Mu F, Briggs A, Swallow E, Rejnmark L 
- 
                                                        Predictors and timing of response to teduglutide in patients with short bowel syndrome dependent on parenteral supportClinical Nutrition ESPEN, 2021 
 2021Chen K, Joly F, Mu F, Kelkar SS, Olivier C, Xie J, Seidner DL 
- 
                                                        Determinants of Hyperkalemia Progression Among Patients with Mild HyperkalemiaAdvances in Therapy, 2021 
 2021Israni R, Betts KA, Mu F, Davis J, Wang J, Anzalone D, Uwaifo GI, Szerlip H, Fonseca V, Wu E 
- 
                                                        Prevalence of Metabolic Acidosis Among Patients with Chronic Kidney Disease and HyperkalemiaAdvances in Therapy, 2021 
 2021Cook EE, Davis J, Israni R, Mu F, Betts KA, Anzalone D, Yin L, Szerlip H, Uwaifo GI, Fonseca V, Wu EQ 
- 
                                                        The Impact of Antipsychotic Dose Reduction on Clinical Outcomes and Health Care Resource Use Among Medicare Patients with SchizophreniaClinical Drug Investigation, 2021 
 2021Zichlin ML, Mu F, Leo S, Ayyagari R 
- 
                                                        Risk of Thromboembolic Events and Associated Risk Factors, Including Treatments, in Patients with Immune-mediated DiseasesClinical Therapeutics, 2021 
 2021Setyawan J, Mu F, Yarur A, Zichlin ML, Yang H, Fernan C, Billmyer E, Downes N, Azimi N, Strand V 
- 
                                                        Risk of Cardiovascular Conditions in Patients with Chronic Hypoparathyroidism: A Retrospective Cohort StudyAdvances in Therapy, 2021 
 2021Gosmanova EO, Chen K, Ketteler M, Rejnmark L, Mu F, Swallow E, Briggs A, Sherry N, Kaul S 
- 
                                                        Risk of Chronic Kidney Disease and Estimated Glomerular Filtration Rate Decline in Patients with Chronic Hypoparathyroidism: A Retrospective Cohort StudyAdvances in Therapy, 2021 
 2021Gosmanova EO, Chen K, Rejnmark L, Mu F, Swallow E, Briggs A, Ayodele O, Sherry N, Ketteler M 
- 
                                                        Risk of Nephrolithiasis and Nephrocalcinosis in Patients with Chronic Hypoparathyroidism: A Retrospective Cohort StudyAdvances in Therapy, 2021 
 2021Ketteler M, Chen K, Gosmanova EO, Signorovitch J, Mu F, Young JA, Sherry N, Rejnmark L 
- 
                                                        
- 
                                                        Hospital utilization rates following antipsychotic dose reduction in mood disorders: implications for treatment of tardive dyskinesiaBMC Psychiatry, 2020 
 2020Caroff SN, Mu F, Ayyagari R, Schilling T, Abler V, Carroll B 
- 
                                                        Postdischarge Health Care Costs and Readmission in Patients With Hyperkalemia-Related HospitalizationsKidney International Reports, 2020 
 2020
- 
                                                        Association of antipsychotic treatment switching in patients with schizophrenia, bipolar, and major depressive disordersJournal of Medical Economics, 2020 
 2020Ayyagari R, Thomason D, Mu F, Philbin M, Carroll B 
- 
                                                        Clinical and Economic Outcomes of Erythropoiesis-Stimulating Agent Hyporesponsiveness in the Post-Bundling EraKidney Medicine, 2020 
 2020Cizman B, Smith HT, Camejo RR, Casillas L, Dhillon H, Mu F, Wu E, Xie J, Zuckerman P, Coyne D 
- 
                                                        The long-term direct and indirect economic burden among Parkinson's disease caregivers in the United StatesMovement Disorders. 2019 Feb;34(2):236-245 
 2019Martinez-Martin P, Macaulay D, Jalundhwala YJ, Mu F, Ohashi E, Marshall T, Sail K 
- 
                                                        Impact of Teduglutide on Quality of Life Among Patients With Short Bowel Syndrome and Intestinal FailureJournal of Parenteral and Enteral Nutrition, 2019 
 2019Chen K, Mu F, Xie J, Kelkar SS, Olivier C, Signorovitch J, Jeppesen PB 
- 
                                                        The prevalence of hyperkalemia in the United StatesCurrent Medical Research and Opinion. 2018 Jun;34(6):971-978 
 2018
- 
                                                        
- 
                                                        Impact of Hidradenitis Suppurativa on Work Loss, Indirect Costs and IncomeBritish Journal of Dermatology, 2018 
 2018Tzellos T, Yang H, Mu F, Calimlim B, Signorovitch J 
- 
                                                        August 24, 2024
- 
                                                    September 11, 2024
- 
                                                    July 19, 2022
- 
                                                    April 5, 2022
- 
                                                    August 18, 2021
- 
                                                    July 20, 2021
